Diabetes mellitus presents a major anaesthetic challenge, with type 1 accounting for approximately 10% and type 2 for 90% of individuals. Rigorous clinical assessment and meticulous perioperative planning strike the necessary balance between avoiding acute hypoglycemia and controlling hyperglycemia to optimize surgical outcomes.
Preoperative Evaluation and Clinical Preparation
Diabetes is diagnosed by repeated HbA1c >48 mmol mol-¹. Glycaemic targets are <54 mmol mol-¹ in primary care with hypoglycaemic drugs and <69 mmol mol-¹ prior to elective surgery. Because significant ischaemic heart disease frequently coexists without warning symptoms, further cardiovascular investigation is often required before major operations. Careful positioning in the operating theatre is mandatory, as sensory loss coupled with peripheral vascular disease predisposes tissues to ulceration from minor trauma. Diabetic autonomic neuropathy presents with postoperative urinary retention and vasomotor instability; hence, intravascular volume must be assessed and euvolaemia achieved before neuraxial needle placement to counter severe hypotension. Day-of-surgery admission is the standard approach, with patients placed first on the list, while preoperative carbohydrate loading protocols must be avoided.
Perioperative Oral Agents and Subcutaneous Insulin
Metformin is taken as usual on once- or twice-daily dosing; on thrice-daily regimens, the lunchtime dose is omitted provided eGFR >60 ml min-¹ and no contrast is required. Sulphonylureas are omitted on the morning of surgery, and fasting patients omit morning doses of meglitinide and acarbose. Pioglitazone, DPP-4 inhibitors, and GLP-1 receptor agonists continue as usual, whereas SGLT-2 inhibitors are omitted for 1 to 2 days prior to or on the day of surgery. Regarding subcutaneous regimens, patients on once-daily morning long-acting insulin receive 80% of their normal dose, while those on twice-daily premixed insulin receive 50% of their morning dose with admission glucose checking, resuming normal evening dosing when eating.
Intraoperative Glycaemic Control and VRIII Protocol
Capillary blood glucose must be recorded at least hourly, targeting 6-10 mmol L-¹ (maximum 12 mmol L-¹). For short starvation (one missed meal), medication modification is preferred and variable-rate intravenous insulin infusions (VRIII) avoided. VRIII is indicated when missing multiple meals, in type 1 diabetes lacking background insulin, in poorly controlled disease, and for emergency surgery. The substrate fluid of choice is 5% dextrose in 0.45% sodium chloride with 0.15% or 0.3% potassium chloride. Patients on VRIII must continue long-acting insulin analogues at 80% of their dose, and infusions must never be discontinued in type 1 diabetes without prior subcutaneous administration. Faulty VRIII management precipitates severe hypoglycaemia, hyperglycaemia, hyponatraemia, and hypokalaemia.
Emergency Crises: DKA and Hyperosmolar Hyperglycaemic State
DKA is defined by ketonaemia >3.0 mmol L-¹ (or ketonuria >2+), blood glucose >11.0 mmol L-¹, and acidaemia (bicarbonate <15 mmol L-¹, venous pH <7.3). Resuscitation commences with 1000 ml of 0.9% saline in the first hour accompanied by a fixed-rate insulin infusion (FRIII) at 0.1 unit kg-¹ h-¹, which must continue until acidosis resolves (pH >7.3, bicarbonate >15 mmol L-¹) because glucose normalisation does not signify resolution. In contrast, HHS features profound hyperglycaemia (>30 mmol/L), hyperosmolality (>320 mOsm/kg), and severe dehydration without marked ketosis (<3 mmol/L) or acidosis. Crucially, all patients with HHS require venous thromboprophylaxis with low molecular weight heparin due to markedly elevated thromboembolic risk.
- Preoperative target HbA1c for elective surgery is <69 mmol mol-¹, with an intraoperative target glucose of 6-10 mmol L-¹ (maximum 12 mmol L-¹).
- Morning insulin is modified on the day of surgery to 80% for once-daily long-acting and 50% for twice-daily premixed formulations.
- The substrate fluid of choice for VRIII is 5% dextrose in 0.45% sodium chloride with KCl, supported by 80% background basal insulin.
- Insulin infusions in type 1 diabetes must never be ceased without prior subcutaneous insulin, and FRIII in DKA continues until acidosis resolves.
- All patients presenting with HHS require thromboprophylaxis using low molecular weight heparin to prevent severe venous thromboembolism.
Sources
- Smith and Aitkenhead's Textbook of Anaesthesia, p. 422
- Smith and Aitkenhead's Textbook of Anaesthesia, p. 423
- Smith and Aitkenhead's Textbook of Anaesthesia, p. 424
- Smith and Aitkenhead's Textbook of Anaesthesia, p. 425
- Smith and Aitkenhead's Textbook of Anaesthesia, p. 425–426
- Smith and Aitkenhead's Textbook of Anaesthesia, p. 426
- Davidson's Principles and Practice of Medicine, p. 814
Test yourself: 24 questions on this topic and many more →
Educational content for healthcare staff and students. It does not replace clinical judgement or your hospital protocol; check any dose against the reference and local guidance before use.